Cardiol Therapeutics - CRDL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 278.38%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$1.85
▼ -0.04 (-2.12%)

This chart shows the closing price for CRDL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cardiol Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRDL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRDL

Analyst Price Target is $7.00
▲ +278.38% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Cardiol Therapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $9.00 and a low forecast of $3.00. The average price target represents a 278.38% upside from the last price of $1.85.

This chart shows the closing price for CRDL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Cardiol Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00Low
6/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00Low
5/23/2024Canaccord Genuity GroupBoost TargetBuy$6.00 ➝ $8.00Low
5/23/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$6.00 ➝ $8.00Low
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00Low
4/22/2024HC WainwrightInitiated CoverageBuy$9.00Low
9/19/2023Leede Jones GabReiterated RatingSpeculative BuyLow
8/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$3.00Low
11/8/2022Raymond JamesLower TargetC$3.00 ➝ C$1.00Low
9/1/2022Raymond JamesLower TargetC$4.00 ➝ C$3.00Low
4/19/2022Canaccord Genuity GroupLower Target$8.00 ➝ $7.00Medium
12/17/2021Cantor FitzgeraldInitiated CoverageOverweight$8.00Medium
8/25/2021Raymond JamesBoost TargetOutperformC$4.50 ➝ C$5.00Medium
8/24/2021Leede Jones GabReiterated RatingSpeculative BuyHigh
(Data available from 6/24/2019 forward)

News Sentiment Rating

0.83 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Cardiol Therapeutics logo
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Read More

Today's Range

Now: $1.85
Low: $1.79
High: $1.89

50 Day Range

MA: $2.18
Low: $1.67
High: $2.97

52 Week Range

Now: $1.85
Low: $0.66
High: $3.12

Volume

306,100 shs

Average Volume

439,176 shs

Market Capitalization

$126.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardiol Therapeutics?

The following equities research analysts have issued stock ratings on Cardiol Therapeutics in the last twelve months: Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, and Leede Jones Gab.
View the latest analyst ratings for CRDL.

What is the current price target for Cardiol Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Cardiol Therapeutics in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 278.4%. HC Wainwright has the highest price target set, predicting CRDL will reach $9.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $3.00 for Cardiol Therapeutics in the next year.
View the latest price targets for CRDL.

What is the current consensus analyst rating for Cardiol Therapeutics?

Cardiol Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRDL will outperform the market and that investors should add to their positions of Cardiol Therapeutics.
View the latest ratings for CRDL.

What other companies compete with Cardiol Therapeutics?

How do I contact Cardiol Therapeutics' investor relations team?

The company's listed phone number is (289) 910-0850 and its investor relations email address is [email protected]. The official website for Cardiol Therapeutics is www.cardiolrx.com. Learn More about contacing Cardiol Therapeutics investor relations.